What question did this study set out to answer?

To identify molecular and immunological features associated with relapse in high-risk neuroblastoma.

April 5, 2026Cancer Research

Multi-Omics Profiling of Neuroblastoma Identifies Immune Biomarkers for Relapse Risk

View Full Paper

Ask AI

Bookmark

To identify molecular and immunological features associated with relapse in high-risk neuroblastoma.
Analyzed tumor and blood samples from 197 neuroblastoma patients using multi-omics approaches.
Utilized whole exome sequencing, RNA sequencing, and plasma cell-free DNA analysis.
Assessed DNA alterations, transcriptomic profiles, immune infiltration, and blood biomarkers.
Higher levels of cfDNA and ctDNA observed at diagnosis in high-risk neuroblastoma patients.
Novel genetic alterations identified at relapse, including ALK and CDKN2A/B.
Increased stemness index associated with relapse risk in high-risk neuroblastoma.
Immune profiles indicated higher CD4+ T-cells but lower NK cells in relapsed patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Multi-omics analysis reveals immunological biomarkers linked to higher relapse risk in high-risk neuroblastoma, highlighting potential therapeutic targets.

Cite This Study

Colaprico et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdb0a79560c99a0a3d7b https://doi.org/10.1158/1538-7445.am2026-1469

View Full Paper

Ask AI

Bookmark

Implication

Multi-omics analysis reveals immunological biomarkers linked to higher relapse risk in high-risk neuroblastoma, highlighting potential therapeutic targets.

Multi-Omics Profiling of Neuroblastoma Identifies Immune Biomarkers for Relapse Risk

Key Points

Discussion

Implication

Cite This Study

Multi-Omics Profiling of Neuroblastoma Identifies Immune Biomarkers for Relapse Risk

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider